Endothelial glycocalyx degradation in multisystem inflammatory syndrome in children related to COVID-19.
COVID-19
Endothelium
Glycocalyx
Heparan sulfate
Inflammation
MIS-C
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
01
07
2021
accepted:
10
03
2022
revised:
09
03
2022
pubmed:
30
3
2022
medline:
20
5
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
Multisystem inflammatory syndrome in children (MIS-C) represents a rare but severe complication of severe acute respiratory syndrome coronavirus 2 infection affecting children that can lead to myocardial injury and shock. Vascular endothelial dysfunction has been suggested to be a common complicating factor in patients with coronavirus disease 2019 (COVID-19). This study aims to characterize endothelial glycocalyx degradation in children admitted with MIS-C. We collected blood and urine samples and measured proinflammatory cytokines, myocardial injury markers, and endothelial glycocalyx markers in 17 children admitted with MIS-C, ten of which presented with inflammatory shock requiring intensive care admission and hemodynamic support with vasopressors. All MIS-C patients presented signs of glycocalyx deterioration with elevated levels of syndecan-1 in blood and both heparan sulfate and chondroitin sulfate in the urine. The degree of glycocalyx shedding correlated with tumor necrosis factor-α concentration. Five healthy age-matched children served as controls. Patients with MIS-C presented severe alteration of the endothelial glycocalyx that was associated with disease severity. Future studies should clarify if glycocalyx biomarkers could effectively be predictive indicators for the development of complications in adult patients with severe COVID-19 and children with MIS-C. KEY MESSAGES : Children admitted with MIS-C presented signs of endothelial glycocalyx injury with elevated syndecan-1 and heparan sulfate level. Syndecan-1 levels were associated with MIS-C severity and correlated TNF-α concentration. Syndecan-1 and heparan sulfate may represent potential biomarkers for patients with severe COVID-19 or MIS-C.
Identifiants
pubmed: 35347344
doi: 10.1007/s00109-022-02190-7
pii: 10.1007/s00109-022-02190-7
pmc: PMC8960079
doi:
Substances chimiques
Biomarkers
0
Syndecan-1
0
Tumor Necrosis Factor-alpha
0
Heparitin Sulfate
9050-30-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
735-746Informations de copyright
© 2022. The Author(s).
Références
Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2250-2260
pubmed: 28602514
Nat Med. 2012 Aug;18(8):1217-23
pubmed: 22820644
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
Front Immunol. 2020 Oct 06;11:575047
pubmed: 33123154
Shock. 2015 May;43(5):450-5
pubmed: 25692257
JAMA. 2020 Aug 18;324(7):663-673
pubmed: 32706371
Crit Care. 2019 Jan 17;23(1):16
pubmed: 30654825
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Br J Clin Pharmacol. 2015 Sep;80(3):389-402
pubmed: 25778676
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1178-1181
pubmed: 32833500
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Crit Care Explor. 2020 Jun 22;2(6):e0144
pubmed: 32696007
J Clin Invest. 2020 Nov 2;130(11):5967-5975
pubmed: 32730233
Clin Pharmacokinet. 2003;42(12):1043-57
pubmed: 12959635
J Clin Pharmacol. 1988 Jul;28(7):609-18
pubmed: 2851016
J Crit Care. 2017 Dec;42:304-309
pubmed: 28822340
Front Immunol. 2020 Apr 03;11:570
pubmed: 32318065
Anesthesiology. 2007 Nov;107(5):776-84
pubmed: 18073553
Respir Med. 2020 Jun;167:105981
pubmed: 32421546
Basic Res Cardiol. 2011 Nov;106(6):1111-21
pubmed: 21769675
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Crit Care Med. 2013 Jul;41(7):1761-73
pubmed: 23685639
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Shock. 2021 Jun 1;55(6):752-758
pubmed: 33021572
Atherosclerosis. 2016 Apr;247:184-8
pubmed: 26926597
J Virol. 2020 Nov 23;94(24):
pubmed: 32999030
Rev Cardiovasc Med. 2020 Sep 30;21(3):315-319
pubmed: 33070537
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
J Pediatric Infect Dis Soc. 2021 Aug 14;10(6):706-713
pubmed: 33180935
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Crit Care. 2015 Apr 24;19:191
pubmed: 25907781
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Ann Surg. 2017 Mar;265(3):597-603
pubmed: 27144442
Circulation. 2007 Oct 23;116(17):1896-906
pubmed: 17923576
Crit Care Explor. 2020 Aug 24;2(9):e0194
pubmed: 32904031
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Crit Care. 2016 Dec;36:125-129
pubmed: 27546760
Front Pediatr. 2021 Jan 05;8:594127
pubmed: 33469522
Pediatr Rheumatol Online J. 2019 Jan 5;17(1):1
pubmed: 30611297
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
Thromb Haemost. 1995 Apr;73(4):630-40
pubmed: 7495071
JAMA. 2021 Mar 2;325(9):855-864
pubmed: 33523115
Angiogenesis. 2021 Feb;24(1):145-157
pubmed: 33058027
Front Oncol. 2014 Jan 14;3:331
pubmed: 24459635
Int J Cardiol. 2019 Oct 1;292:236-240
pubmed: 31200965
Cell. 2020 Nov 12;183(4):982-995.e14
pubmed: 32991843
Shock. 2015 Dec;44(6):569-77
pubmed: 26529654
N Engl J Med. 1972 Aug 17;287(7):324-7
pubmed: 5041701
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578